CD19 and B-cell non-Hodgkin lymphoma: The results of the presented pivotal trials and subsequent FDA approval of four different CD19-directed CAR-T products for the treatment of a spectrum of R/R B-cell lymphomas have dramatically improved patient outcomes [4,5,6,7].